Zinc l-carnosine in gastric ulcers: a profile of its use
- 37 Downloads
Oral zinc l-carnosine (Gastrozin®) 75 mg twice daily is an effective gastric mucoprotective option for the treatment and prevention of gastric ulcers. The two components of the chelated compound (i.e. zinc and l-carnosine in a 1:1 ratio) provide beneficial anti-inflammatory, antioxidant and other effects that work together to support the natural mucoprotective mechanisms of the gastrointestinal tract. Zinc l-carnosine 75 mg twice daily has well established efficacy in the treatment of gastric ulcers, and is at least as effective as other mucoprotectants in this indication. It consistently provides rapid healing of gastric ulcers regardless of their underlying cause, such as gastritis, Helicobacter pylori infection and endoscopic submucosal dissection (ESD), or concurrent pharmacological treatment (e.g. H. pylori eradication or proton pump inhibitor therapy).
The manuscript was reviewed by: H. Parthasarathy, Department of Cardiology, Apollo Hospitals, Chennai, India, Y. Prashar, Department of Pharmacology, Rayat Institute of Pharmacy, Railmajra, India; S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India; A.K. Srivastava, Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, India. During the peer review process, Synergy Pharma, the marketing-authorization holder of the Gastrozin® formulation of zinc l-carnosine, was also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
KA. Lyseng-Williamson is an employee of Adis International Ltd./Springer Nature and the Editor of Drugs & Therapy Perspectives; she has no other conflicts of interest to declare. The Editor of D&TP was not involved in any publishing decisions for the manuscript.
- 1.Choi HS, Kim ES, Keum B, et al. l-carnosine and zinc in gastric protection. In: Preedy VR, editor. Food and Nutritional Components in Focus. Cambridge: Royal Society of Chemistry; 2015. p. 548–65.Google Scholar
- 2.Myran L, Zarbock SD. Management of Helicobacter pylori infection. US Pharm. 2019;43(4):27–32.Google Scholar
- 3.Gastrozin (75 mg zinc l-carnosine tablet): package leaflet. Dubai: Synergy Pharma. 2019.Google Scholar
- 4.Hudson T. Nutrient profile: zinc-carnosine: a combination of zinc and l-carnosine improves gastric ulcers. Natural Med J. 2013;5:11.Google Scholar
- 5.Matsukura T, Tanaka H. Applicability of zinc complex of l-carnosine for medical use. Biochem (Mosc). 2000;65(7):817–23.Google Scholar
- 6.Soderberg TA, Sunzel B, Holm S, et al. Antibacterial effect of zinc oxide in vitro. Scan J Plast Reconstr Sug Hand Surg. 1990;24(3):93–107.Google Scholar
- 11.Gaby AR. Therapeutic agents part 2B: minerals. Nutritional medicine. 2nd ed. Concord (NH): Nutritional Medicine. 2017.Google Scholar
- 20.Ito M, Shii D, Segami T, et al. Preventive actions of N-(3-aminopropionyl)-l-histidinato zinc (Z-103) through increases in the activities of oxygen-derived free radical scavenging enzymes in the gastric mucosa on ethanol-induced gastric mucosal damage in rats. Jpn J Pharmacol. 1992;59(3):267–77.CrossRefGoogle Scholar
- 35.Miyoshi A, Matsuo H, Miwa T, et al. Clinical evaluation of Z-103 in the treatment of gastric ulcers: a multicenter double-blind dose finding study [in Japanese]. Jpn Pharmacol Ther. 1992;20(1):181–97.Google Scholar
- 36.Miyoshi A, Namiki M, Iwasaki A, et al. Clinical evaluation of Z-103 in the treatment of gastritis: a multicenter double-blind dose finding study [in Japanese]. Jpn Pharmacol Ther. 1997;25(5):1403–42.Google Scholar
- 37.Miyoshi A, Matsuo H, Miwa T, et al. Clinical evaluation of Z-103 in the treatment of gastritis: an open-label dose finding study [in Japanese]. Jpn Pharmacol Ther. 1992;20(1):245–54.Google Scholar
- 38.Miyoshi A, Matsuo H, Miwa T, et al. Clinical evaluation of Z-103 (polaprezinc) on gastric ulcer: a multicenter double-blind comparative study with cetraxate hydrochloride [in Japanese]. Jpn Pharmacol Ther. 1992;20(1):199–223.Google Scholar
- 39.Nakajima M. Clinical evaluation of Z-103 on gastritis: a double-blind controlled study using sucralfate as a comparator. Pharmacol Ther. 1997;25(4):325–66.Google Scholar
- 42.Sugimoto N, Yoshikawa T, Naito Y, et al. Triple therapy of lansoprazole + amoxicillin + metronidazole versus triple plus mucosal protective drug polaprezinc therapy for cure of Helicobacter pylori (HP) in gastric ulcer patients [abstract]. Gastroenterology. 1997;112:A300.Google Scholar
- 43.Baniya R, Upadhaya S, Chughtai K, et al. Is polaprezinc a missing link in Helicobacter pylori eradication therapy? A meta-analysis of randomized controlled trials of triple therapy with polaprezinc [abstract no. 1249]. Am J Gastroenterol. 2017;112(Suppl 1):S680-S1.Google Scholar
- 46.Jung DH, Park JC, Lee YC, et al. Comparison of the efficacy of polaprezinc plus proton pump inhibitor and rebamipide plus proton pump inhibitor treatment for ESD-induced gastric ulcers: a randomized prospective controlled study [abstract no. Mo1107]. Gastrointest Endosc. 2017;85(5 Suppl 1):AB431.CrossRefGoogle Scholar
- 47.Dajani A, Abuhammour A. A modified sequential regimen of Helicobacter pylori treatment enforced by Bacillus clausii and zinc carnosine complex yields high eradication rates [abstract no. P-0040]. J Gastroenterol Hepatol. 2017;32(Suppl 3):61–2.Google Scholar
- 48.Dajani AI, Nounou MA, Fayadh MH, et al. Zinc carnosine complex improves the response to triple therapy of Helicobacter pylori eradication [abstract no. P-0279]. J Gastroenterol Hepatol. 2017;32(Suppl 3):72.Google Scholar